Prevent an allergic reaction from happening at school.

Brompheniramine Maleate

Pronunciation: BROME-fen-IR-a-meen MAL-ee-ate
Class: Antihistamine, Alkylamine, nonselective

Trade Names

J-Tan PD
- Liquid, oral 1 mg/mL

Pharmacology

Competitively antagonizes histamine at H 1 receptor sites.

Slideshow: The Shocking Truth About Antibiotic Resistance

Pharmacokinetics

Absorption

T max is approximately 5 h.

Elimination

Major route of elimination is urinary excretion. Half-life is approximately 25 h.

Indications and Usage

Relief of sneezing; itchy, watery eyes; itchy nose or throat; and runny nose because of hay fever (allergic rhinitis) or other upper respiratory allergies.

Contraindications

None well documented.

Dosage and Administration

Children 6 to 12 y of age

PO 2 dropperfuls (2 mL) every 4 to 6 h, up to 12 dropperfuls (12 mL) in 24 h.

Children 2 to younger than 6 y

PO 1 dropperful (1 mL) every 4 to 6 h, up to 6 dropperfuls (6 mL) in 24 h.

Storage/Stability

Store at 59° to 86°F.

Drug Interactions

Alcohol, CNS depressants (eg, sedatives, tranquilizers)

Effects may be enhanced by brompheniramine.

Sodium oxybate

Coadministration may result in increased sleep duration and CNS depression. Coadministration is contraindicated.

Adverse Reactions

CNS

Drowsiness; excitability.

Precautions

Monitor

Assess allergy symptoms (eg, cough; rhinitis; nasal congestion; sneezing; watery eyes; itchy nose, throat, or eyes) before starting therapy and periodically during therapy.


Pregnancy

Category undetermined . Exposure near the birth of premature infants has been associated with an increased risk of retrolental fibroplasia.

Lactation

Excreted in breast milk.

Elderly

Per the Beers criteria, avoid use in elderly patients.

Special Risk Patients

Use with caution in patients with respiratory disorders (eg, chronic bronchitis) or glaucoma.

CNS effects

May cause drowsiness. Excitability may occur, especially in children.

Overdosage

Symptoms

No data available.

Patient Information

  • Inform patients not to exceed the recommended dosage and to discontinue use and contact a health care provider if new symptoms occur.
  • Inform patients that drowsiness may occur; excitability may also occur, especially in children.
  • Advise patients to avoid activities that require mental alertness and motor coordination until they know how the medication affects them.
  • Advise patients to avoid alcohol and that use with other CNS depressants may cause additive drowsiness.
  • Advise patients to check with their health care provider prior to use if they have glaucoma or a respiratory disorder (eg, chronic bronchitis), or if they are pregnant or breast-feeding.

Copyright © 2009 Wolters Kluwer Health.

Hide
(web5)